Program Aims
Identify, develop, and apply immunotherapy-based approaches for the treatment of cancer and elucidate strategies to suppress adverse effects
Objectives in DDT immuno-oncology research are to uncover novel mechanistic insights, harness the immune system to eliminate cancer, and bring novel immunotherapeutic approaches into the clinic, benefitting cancer patients in our Catchment Area. Since these therapies are often associated with adverse effects from enhanced activation of the immune system, another focus is to develop strategies that attenuate systemic and organ-specific immunological toxicities.
Develop and employ imaging and radiotherapy strategies to optimize cancer treatment and increase therapeutic index
DDT strives to develop and apply innovative cancer imaging approaches to accurately characterize the extent of tumor involvement and measure response to chemotherapy, radiotherapy (RT), and immunotherapy. Program Members also seek to advance a precision medicine approach to RT by developing strategies that reduce toxicities through real-time sequential modification of radiation fields via practice-changing computational modeling.
Discover and therapeutically target drivers of cancer initiation, progression, and metastasis
A significant focus of the DDT Program is the identification and development of therapeutic strategies that target cancer drivers and pathways enabling resistance to hormonal, biological, small molecule, and chemotherapeutic anticancer agents. DDT Members also evaluate and target treatment-refractory cancers and rare cancers with the objective of providing tailored therapy based on their unique molecular signatures.
Drug Therapy Offers New Hope for Patients with Mantle Cell Lymphoma
Groundbreaking results from a recent clinical trial found that Pirtobrutinib significantly improved life expectancy for patients with mantle cell lymphoma who responded poorly to other treatments. These results led to accelerated approval of Pirtobrutinib by the Food and Drug Administration.
Patients Receive 鈥淩ockstar鈥� Treatment for Chronic Graft-Versus-Host Disease
果冻影院 Cancer Center scientists conducted a pivotal trial leading to the expedited FDA approval of REZUROCK, a ground-breaking new therapy that works by rebalancing a patient鈥檚 immune system.
CAR-T Therapy Slows Multiple Myeloma in Patients Who Have Stopped Responding to Other Treatments
In a Phase 3 study, 果冻影院 Cancer Center investigators found that patients with Multiple Myeloma who were treated with a unique CAR-T therapy experienced significantly positive results, findings which could lead to a new standard of care for the treatment of this disease.
Program Leaders
William R. Drobyski, MD
Mariette C. and Philip W. Orth/Tom Anderson Chair of Oncology; Professor, Medicine (Hematology/Oncology), Pediatrics, Microbiology & Immunology
